Ardelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS

MT Newswires Live11-09

Ardelyx (ARDX) shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.

The company was looking to block the health agency's plan to include Xphozah and other oral-only phosphate lowering therapies in its end-stage renal disease prospective payment system. It argued that the plan would make it difficult for patients to access the drugs.

However, Judge Beryl Howell of the US District Court for Washington, DC, decided against Ardelyx and allowed CMS to move forward with its rule which would take effect starting in 2025.

Ardelyx said it was reviewing the court's decision and will consider all options related to the lawsuit.

Ardelyx was joined by the American Association of Kidney Patients and the National Minority Quality Forum in the lawsuit.

Price: 4.99, Change: -1.40, Percent Change: -21.87

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482360754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482360754","market":"sg","top_or_hot":-1,"title":"Ardelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> (ARDX) shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.</p><p>The company was looking to block the health agency's plan to include Xphozah and other oral-only phosphate lowering therapies in its end-stage renal disease prospective payment system. It argued that the plan would make it difficult for patients to access the drugs.</p><p>However, Judge Beryl Howell of the US District Court for Washington, DC, decided against Ardelyx and allowed CMS to move forward with its rule which would take effect starting in 2025.</p><p>Ardelyx said it was reviewing the court's decision and will consider all options related to the lawsuit.</p><p>Ardelyx was joined by the American Association of Kidney Patients and the National Minority Quality Forum in the lawsuit.</p><p>Price: 4.99, Change: -1.40, Percent Change: -21.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Shares Fall After Federal Judge Dismisses Lawsuit Against CMS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 02:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ardelyx (ARDX) shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.The company was looking to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4208","symbol_name":"复合型公用事业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482360754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482360754","pubTimestamp":1731091186,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ardelyx  shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.The company was looking to block the health agency's plan to include Xphozah and other oral-only phosphate lowering therapies in its end-stage renal disease prospective payment system. It argued that the plan would make it difficult for patients to access the drugs.However, Judge Beryl Howell of the US District Court for Washington, DC, decided against Ardelyx and allowed CMS to move forward with its rule which would take effect starting in 2025.Ardelyx said it was reviewing the court's decision and will consider all options related to the lawsuit.Ardelyx was joined by the American Association of Kidney Patients and the National Minority Quality Forum in the lawsuit.Price: 4.99, Change: -1.40, Percent Change: -21.87","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4208":"复合型公用事业","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4585":"ETF&股票定投概念","ARDX":"Ardelyx","BK4139":"生物科技","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","CMS":"CMS能源"},"translate_title":"联邦法官驳回针对CMS的诉讼后Ardelyx股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"US7Y.BOND":1,"US6M.BOND":1,"US5Y.BOND":1,"CMS":1,"US3Y.BOND":1,"US30Y.BOND":1,"US2Y.BOND":1,"ARDX":1,"US10Y.BOND":1,"US12M.BOND":1,"US912797HE00.BOND":0.6},"content_text":"Ardelyx (ARDX) shares fell nearly 22% in recent trading Friday after a federal judge dismissed the company's lawsuit against the Centers for Medicare and Medicaid Services.The company was looking to block the health agency's plan to include Xphozah and other oral-only phosphate lowering therapies in its end-stage renal disease prospective payment system. It argued that the plan would make it difficult for patients to access the drugs.However, Judge Beryl Howell of the US District Court for Washington, DC, decided against Ardelyx and allowed CMS to move forward with its rule which would take effect starting in 2025.Ardelyx said it was reviewing the court's decision and will consider all options related to the lawsuit.Ardelyx was joined by the American Association of Kidney Patients and the National Minority Quality Forum in the lawsuit.Price: 4.99, Change: -1.40, Percent Change: -21.87","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482360754"}